You are here: Industry Insights > MES

News List

The Role of Exosomes in Drug Delivery: A Natural Alternative to Synthetic Nanocarriers? Nurah Ekhlaque
April 09, 2025
Explore how exosome-based nanocarriers are shaping precision medicine by supporting targeted drug delivery in cancer and neurodegenerative diseases, with potential for reduced side effects.
Professor James Rothman, Nobel Laureate, to Join the Board of Noscendo GmbH Biotech Newswire
August 21, 2024
Noscendo GmbH announced that Professor James Rothman has agreed to serve on its board as an independent director.
Advances in Research on New Therapeutic Drugs for Myelodysplastic Syndromes (Part Two) Xiaomichong
July 09, 2024
In recent years, with the deepening of research into the pathogenesis of myelodysplastic syndromes (MDS), many novel drugs have emerged.
Advances in Research on New Therapeutic Drugs for Myelodysplastic Syndromes (Part one) Xiaomichong
July 09, 2024
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic malignancies characterized by defective normal hematopoiesis leading to a reduction in blood cells, with a risk of transformation into acute myeloid leukemia.
From CDMO Pharmaceutical Crisaborole First Generic Drug, Look at the Domestic PDE-4 Inhibitor R&D Development Layout Xiaobin
May 06, 2024
The NMPA official website showed that Zhejiang CDMO Pharmaceutical had submitted an application for the marketing application of crisaborole ointment as a generic drug and it was accepted by the Center for Drug Evaluation.
Vetter Becomes a Member of the German Association of Research-Based Pharmaceutical Companies (vfa) B3C newswire
January 19, 2024
?Globally operating CDMO committed to strengthening Germany as a research and production location Association grants Vetter extraordinary membership.
Domestic New Drug R&D Strength is Gradually Ascending, and Overseas Product Authorization is in Full Swing WND/PharmaSources
December 14, 2023
On November 13th, LEGN.US reached an 1 billion US dollar cooperation agreement with Novartis Pharmaceuticals.
Next Stop for PD-1? MNC for Subcutaneous Preparation Takes the Lead in Competition, Leading to A More Fierce Domestic Conpetition, but Differentiation is not easy Spur 203/PharmaSources
December 14, 2023
The competition for the subcutaneous formulation of PD-1/PD-L1 inhibitors has been spreading globally for a long time, with Roche and Bristol Myers Squibb currently leading the pack.
Initial CRISPR Gene Editing Therapy has been Approved. What is the Domestic Progress? Yefenghong/PharmaSources
December 14, 2023
Vertex Pharmaceuticals and CRISPR Therapeutics announced that their jointly developed CRISPR gene editing therapy CASGEVY has been conditionally approved.
Great Market Potential: Important Nodes in the Domestic RSV Pharmaceutical Field Xiaoyaowan
December 14, 2023
Respiratory syncytial virus (RSV) is a common enveloped RNA virus that circulates in the winter and spring. It is mainly transmitted by direct contact with the nasal secretions and respiratory droplets of infected individuals.